Comparative Pharmacology
Head-to-head clinical analysis: ADVIL versus VIVLODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL versus VIVLODEX.
ADVIL vs VIVLODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby reducing pain, fever, and inflammation.
COX-2 inhibitor; reduces prostaglandin synthesis via inhibition of cyclooxygenase-2 (COX-2) with minimal COX-1 inhibition.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day (OTC). For prescription: 400-800 mg orally 3-4 times daily; maximum 3200 mg/day.
Once daily oral administration of 100 mg or 200 mg capsules. The recommended dose is 100 mg once daily; dose may be increased to 200 mg once daily if response is inadequate. Maximum daily dose: 200 mg.
None Documented
None Documented
2-4 hours (terminal elimination half-life in adults; prolonged in overdose or renal impairment: up to 8-12 hours)
Terminal elimination half-life of the active moiety meloxicam is approximately 20 hours (range 12-24 h), allowing once-daily dosing in chronic pain.
Renal: ~95% (hepatic metabolites and conjugates, <1% unchanged); biliary/fecal: ~5%
VIVLODEX is a meloxicam NSAID prodrug. Following hydrolysis to meloxicam, excretion is primarily hepatic (metabolism) and renal (urine). Approximately 50% of meloxicam dose is excreted in urine as metabolites and <5% as parent drug; about 40% in feces. Biliary excretion is minor.
Category C
Category C
NSAID
NSAID